ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 2.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 423,947 shares of the company’s stock after purchasing an additional 8,417 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in ARS Pharmaceuticals were worth $6,147,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. First Turn Management LLC acquired a new position in ARS Pharmaceuticals in the third quarter valued at approximately $8,603,000. SG Americas Securities LLC grew its holdings in shares of ARS Pharmaceuticals by 861.5% during the 2nd quarter. SG Americas Securities LLC now owns 111,592 shares of the company’s stock worth $950,000 after purchasing an additional 99,986 shares during the period. Royce & Associates LP grew its holdings in shares of ARS Pharmaceuticals by 7.1% during the 3rd quarter. Royce & Associates LP now owns 691,455 shares of the company’s stock worth $10,026,000 after purchasing an additional 45,755 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in shares of ARS Pharmaceuticals during the third quarter valued at about $2,584,000. Finally, Bank of New York Mellon Corp increased its holdings in ARS Pharmaceuticals by 99.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 139,285 shares of the company’s stock valued at $1,185,000 after purchasing an additional 69,394 shares during the last quarter. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on SPRY. Leerink Partners boosted their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research note on Friday, September 20th. William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $24.00.

ARS Pharmaceuticals Trading Down 5.3 %

Shares of ARS Pharmaceuticals stock opened at $12.27 on Thursday. The company has a fifty day simple moving average of $14.69 and a 200-day simple moving average of $12.32. ARS Pharmaceuticals, Inc. has a 12-month low of $5.01 and a 12-month high of $18.51. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -24.06 and a beta of 0.88.

Insiders Place Their Bets

In other news, insider Eric Karas sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the transaction, the insider now owns 5,693 shares of the company’s stock, valued at approximately $79,702. The trade was a 63.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Richard E. Lowenthal sold 100,000 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $12.93, for a total value of $1,293,000.00. Following the sale, the chief executive officer now directly owns 1,398,499 shares of the company’s stock, valued at approximately $18,082,592.07. This represents a 6.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,215,786 shares of company stock valued at $18,999,286. 40.10% of the stock is currently owned by insiders.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.